Johnson & Johnson (NYSE:JNJ) Shares Bought by Wealth Alliance LLC

Wealth Alliance LLC raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 36.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,009 shares of the company's stock after acquiring an additional 6,173 shares during the quarter. Wealth Alliance LLC's holdings in Johnson & Johnson were worth $3,816,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Johnson & Johnson by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after purchasing an additional 1,772,706 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock valued at $8,321,881,000 after purchasing an additional 1,561,036 shares in the last quarter. Northern Trust Corp boosted its holdings in Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after purchasing an additional 3,363,235 shares in the last quarter. Norges Bank acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $4,390,037,000. Finally, Wellington Management Group LLP boosted its holdings in Johnson & Johnson by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock valued at $3,522,447,000 after purchasing an additional 431,205 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $163.65 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $393.75 billion, a price-to-earnings ratio of 17.50, a PEG ratio of 2.19 and a beta of 0.41. The stock's fifty day simple moving average is $154.29 and its 200 day simple moving average is $155.05. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.82 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.18%. Johnson & Johnson's payout ratio is presently 55.61%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Royal Bank Of Canada increased their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Guggenheim increased their target price on Johnson & Johnson from $164.00 to $167.00 and gave the stock a "neutral" rating in a research report on Thursday. Finally, Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $172.87.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.